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Update of Antibiotic Therapy of 
Brucellosis
Sara Consuelo Arias Villate and Julio Cesar García Casallas
Abstract
Currently, the only option for treating brucellosis is antibiotics especially to 
prevent complications. In this chapter, we want to talk about the drug therapy in 
brucellosis and the update of these therapies in the last years. Also, we will expose 
the principal antibiotics in brucellosis such as doxycycline, rifampin, streptomycin, 
cotrimoxazole (TMP/SMX), and gentamicin by talking about each one of their 
mechanism of action, pharmacokinetics, administration, risk assessment, adverse 
effects, and principal drug interactions. Furthermore, we will add the evidence of 
efficacy therapy in monotherapy or combinate therapy based on the evidence.
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1. Introduction
Brucellosis is a zoonotic disease that can affect humans around the world, and it 
can affect any organ system. About the treatment, it is characterized to be prolonged 
therapy with a concomitant use of at least two or three antibiotics at different admin-
istration routes. The antibiotics have some special indications for administration, 
interactions, and risk assessment to prevent adverse reactions. That is why we will 
expose the principal antibiotics in brucellosis treatment based on the last evidence.
2. Antibiotic treatment
The principal objective of the treatment in brucellosis is to control the disease, 
prevent complications, relapse, and unfavorable outcomes. In the context of a zoonotic 
infection, the goal of its management is an appropriate antibiotic therapy with a pro-
longed duration of treatment, nevertheless the most effective antibiotic and treatment 
durations are unclear. Also, there are some limitations to choose the best treatment 
because of the need to choose antibiotics that act intracellularly and to prevent relapses 
with a prolonged therapy that can lead to increase the adverse effects of the drugs [1].
Furthermore, the monotherapy for brucellosis has been considered inadequate due 
to unacceptably high relapse rates, now we present possible treatment schemes [2, 3].
Uncomplicated brucellosis: (defined by not having focal disease like spondylitis, 
neurobrucellosis or endocarditis, and adults or > 30 kg):
• Doxycycline 100 mg orally twice daily for 6 weeks, plus streptomycin 1 g intra-
muscularly one daily for the first 14–21 days (or gentamicin 5 mg/kg for 5–14 days) 
[1, 2, 4].
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• Doxycycline 100 mg orally twice daily plus rifampin 600–900 mg (15 mg/kg) 
orally one daily for 6 weeks [1, 3].
• Consider triple therapy with addition of amikacin (intramuscularly twice a day 
for 7 days) to relief symptoms more rapid.
Alternative agents: (they may be useful in the setting of drug resistance, allergy, 
antimicrobial toxicity or relapse in combination with doxycycline or rifampin)
• Ciprofloxacin 500 mg twice daily or ofloxacin 200 mg twice daily [5, 6].
• Trimethoprim-sulfamethoxazole (TMP-SMX) one double-strength tablet 
twice a day.
Focal disease: spondylitis, neurobrucellosis, endocarditis, or localized suppura-
tive lesions (it requires longer courses of therapy at least 12 weeks):
• Spondylitis
 ○ Doxycycline 100 mg orally twice daily for 12 weeks plus streptomycin 1 g intra-
muscularly once daily for the first 14–21 days [7].
 ○ Alternative: doxycycline 100 mg orally twice daily plus rifampin 600–900 mg 
(15 mg/kg) once daily for 12 weeks.
 ○ Surgery in the context of spinal instability, persistence or progression of neuro-
logical deficit or localizes abscess epidural or paravertebral [8].
• Neurobrucellosis
 ○ Doxycycline, rifampin, and ceftriaxone or TMP-SMX.
 ○ Corticosteroids may be appropriate in the setting of neurobrucellosis complicated 
by iritis, papilledema, myelopathy, polyneuropathy, or cranial nerve palsies.
• Endocarditis
 ○ Doxycycline plus rifampin 300 mg every 12 h and gentamycin 5 mg/kg  
each day, the duration of therapy is uncertain usually for 6 weeks to 
6 months [9].
 ○ Surgery: valve replacement.
Pregnant women: [2, 10].
• Limited data.
• Rifampin 900 mg once daily, with or without TMP-SMV (one double-strength 
tablet twice a day) for 6 weeks or rifampin with ceftriaxone.
Children
• Uncomplicated brucellosis
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 ○ (<8 years of age): oral TMP-SMX [10 mg/kg per day TMP (maximum 
480 mg/day) and 50 mg/kg per day SMX (maximum 2.4 g/day) by mouth 
divided into two doses] daily plus rifampin [15–20 mg/kg per day by mouth 
(maximum 900 mg/day) divided in one or two doses] (or gentamycin 5 mg/
kg IV daily for 7 days) for 6 weeks [10–12].
 ○ (>8 years of age): oral doxycycline [2–4 mg/kg per day by mouth (maximum 
200 mg/day) divided into two doses] or tetracycline [30–40 mg/kg per day 
by mouth (maximum 2 g/day) divided into four doses] plus rifampin for 
6 weeks [11].
• Osteoarticular disease, neurobrucellosis, or endocarditis
 ○ <8 years of age: oral TMP-SMX for at least 6 weeks plus parenteral aminogly-
coside [gentamicin (5 mg/kg per day parenterally divided into one to three 
doses) or streptomycin (20–40 mg/kg per day (maximum dose 1 g/day) 
parenterally divided in two doses)] for the first 14 days of therapy.
 ○ >8 years of age: oral doxycycline or tetracycline for at least 6 weeks, plus 
parenteral aminoglycoside (gentamicin or streptomycin) for the first 14 days 
of therapy.
2.1 Doxycycline
2.1.1 Mechanism of action
It belongs to the group of tetracyclines that are a series of derivatives of basic 
four-ring structure. Doxycycline inhibits bacterial protein synthesis by binding to 
the 30S bacterial ribosome and blocking the access of aminoacyl tRNA to  
the A (acceptor) site on the mRNA-ribosome complex and inhibits protein  
synthesis [13].
2.1.2 Antimicrobial activity
Doxycycline is a bacteriostatic antibiotic with activity against Streptococcus 
pneumoniae and H. influenzae and excellent activity against atypical pathogens such 
as Mycoplasma and Chlamydophila pneumoniae, methicillin-resistant Staphylococcus 
aureus and methicillin-susceptible Staphylococcus aureus, Bacillus anthracis, and 
Listeria monocytogenes and most strains of Brucella are susceptible. Some species 
such as Pseudomonas aeruginosa are resistant [13, 14].
2.1.3 Pharmacokinetics
See Table 1.
2.1.4 Administration
• Oral: administer with meals to decrease gastrointestinal (GI) discomfort. 
Administer capsules and tablets with a considerable amount of water and have 
patient sit up for at least 30 minutes to reduce esophageal irritation. Oral admin-
istration is preferable unless patient has significant nausea and vomiting [13].
• IV: infuse prolonged over 1–4 hours to prevent thrombophlebitis.
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2.1.5 Risk assessment
When therapy of doxycycline needs to be used in prolonged therapy, some 
parameters need to be taken to prevent some of the adverse effects: complete 
blood count (CBC), renal and liver function tests periodically, during  
therapy [13].
2.1.6 Adverse effects
• Gastrointestinal: it can produce GI irritation especially after oral admin-
istration (epigastric burning, abdominal discomfort, nausea, vomiting 
and diarrhea). To prevent this, the patient should take oral formulations with 
a glass full of water, administration on an empty stomach is generally not 
recommended [14].
• Photosensitivity: it may produce photosensitivity reactions in treated individu-
als exposed to sunlight. The patient needs to use skin protection and avoid 
prolonged exposure to sunlight and ultraviolet light [14].
• Hepatotoxicity: rarely occurs during the treatment. If patient became symptomatic, 
assess liver function tests, and discontinue drug [14].
• Hypersensitivity syndromes: severe skin reactions have been reported. Discontinue 
therapy for serious hypersensitivity reactions.
• Superinfection: prolonged use may result in fungal or bacterial superinfection 
like pseudomembranous colitis.
• Tissue hyperpigmentation: may induce hyperpigmentation in many organs: 
nails, bone, skin, eyes, thyroid, oral cavity (permanent brown discoloration 
of the teeth in children <8 years or in children from pregnant women in 
their last half of pregnancy), and sclerae, most dependently of time and 
chronic use [15].
2.1.7 Principal drug interactions
See Table 2.
Absorption Oral: almost completely absorbed from the gastrointestinal tract (GI) (90–100%), plasma 
concentration may be reduced 20% by high-fat meal or milk
Time to peak serum: oral: 2–4 hours
Distribution Widely distributed into tissues and fluids including synovial, pleural, prostatic, seminal 
fluids and bronchial secretions, saliva, aqueous humor
Poor cerebrospinal fluid penetration
Protein binding: >90%
Distribution volume
Bioavailability: reduced at high pH
Metabolism Not hepatic, partially inactivated in GI tract by chelate formation
Elimination Half-time elimination: 18–22 hours, end-stage renal disease: 18–25 hours
Excretion: feces (30%); urine (23–40%)
Table 1. 
Pharmacokinetics parameters of doxycycline [13].
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2.1.8 Important
• Tetracyclines are inexpensive, widely available, and poor associated with side 
effects, and also it have proven safe in all age groups [21].
• The doxycycline-streptomycin regimen is considered the first line and has been 
proven to be more effective than doxycycline-rifampin in some studies [4, 22].
• Do not administer to children <8 years of age due to permanent discoloration 
of teeth, retardation of skeletal development, and bone growth; more common 
with long-term use, but may be observed with repeated, short courses [12, 23].
2.2 Streptomycin
2.2.1 Mechanism of action
It is an aminoglycoside antibiotic bactericidal. Aminoglycosides diffuse through 
aqueous channels formed by porin proteins in the outer membrane of Gram-
negative bacteria to enter to the periplasmic space, and its transport across the cyto-
plasmic membrane depends on an electrical gradient coupled to electron transport 
to drive permeation of these antibiotics. That is why they are not used in anaerobic 
environments of abscess. Once streptomycin is inside the cell, it binds to the 30S 
ribosomal subunit and interferes with protein synthesis by causing misreading and 
Drug Risk rating Interaction Mechanism Management
Antacids 
(aluminum 
hydroxide, 
calcium 
carbonate, 
magnesium 
carbonate, 
sodium 
bicarbonate)
Consider 
therapy 
modification
Antacids may 
decrease the 
absorption of 
doxycycline
Formation of 
chelates between 
antibiotic 
and antacids 
that reduces 
absorption from 
the GI tract [16]
Separate 
administration of 
both by a few hours 
when possible
Monitor for 
decreased 
therapeutic effects 
of antibiotic [17]
Barbiturates Consider 
therapy 
modification
Barbiturates 
may decrease 
the serum 
concentration of 
doxycycline
Uncertain. 
Induction of 
doxycycline 
metabolism or 
excretion by the 
barbiturates [18]
Monitor decreased 
therapeutic effects 
of antibiotic if used 
concurrently with a 
barbiturate
Aspirin Monitor 
therapy
Aspirin may 
decrease 
the serum 
concentration of 
doxycycline
Buffered aspirin 
contains antacids 
that alkaline 
environment 
may also reduce 
absorption [19]
Administer 
doxycycline at least 
2 hours before or 
6 hours after aspirin 
ingestion
Rifampin Monitor 
therapy
Rifampin 
may decrease 
the serum 
concentration of 
doxycycline
Unknown. 
Rifampin 
induction of 
doxycycline 
metabolism and/
or excretion [20]
Monitor closely for 
reduced doxycycline 
response in patients 
receiving rifampin
Table 2. 
Principal drug interactions of doxycycline.
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premature termination of mRNA translation, and the resulting aberrant proteins 
may be inserted into the cell membrane altering permeability [24–26].
2.2.2 Antimicrobial activity
It is less active than other members of the class against aerobic Gram-negative, 
and it is used for the treatment of unusual infections and in combination with 
other antimicrobial agents. The inhibitory activity of aminoglycosides persists after 
the serum concentration has fallen below de minimum inhibitory concentration 
(MIC), and it is known as the post antibiotic effect and it improves the efficacy of 
high-dose extended-interval dosing regimens for aminoglycoside. It is used for the 
treatment of tuberculosis, tularemia, severe M. avium complex, brucellosis, and 
enterococcal endocarditis in combination with other drugs [24, 27].
2.2.3 Pharmacokinetics
See Table 3.
2.2.4 Administration
Streptomycin may be administered by deep intramuscular injection into large 
muscle mass, rotate injection sites (it may be painful with a hot tender mass develop-
ing at the site injection) or intravenously (after dilution in admixture, infuse over 
30–60 minutes). High-dose, extended-interval administration is the preferred admin-
istration of aminoglycosides because of less toxic effect than divided doses [24, 27].
2.2.5 Risk assessment
It is important to monitor hearing tests (baseline and periodic audiograms), 
BUN, creatinine, and serum drug concentrations should be monitored in all patients:
• Therapeutic peak: 20–30 mcg/mL [25].
2.2.6 Adverse effects
• Ototoxicity: aminoglycoside induces ototoxicity irreversible, bilateral, high- 
frequency hearing loss or vestibular hypofunction. It has been seen degeneration 
of hair cells and neurons in the cochlea and accumulation in the perilymph and 
endolymph at high antibiotic concentration in plasma. The initial symptoms such 
Absorption Oral: poorly absorbed, IM: well absorbed
Time to peak IM: 1–2 hours
Distribution Into most body tissues and fluids except the brain and adipose tissue (because of their polar 
nature)
Protein binding: 34%
Volume of distribution (Vd): 260 mL/kg
Metabolism None known
Excretion Half-time elimination: adults: 2–4, 7 hours, prolonged with renal impairment
Urine: 29–89% as unchanged drug
Bile, saliva, sweat and tears: (1%)
Table 3. 
Pharmacokinetic parameters of streptomycin [24, 28].
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as high-pitched tinnitus, nausea, vomiting, and difficulty in equilibrium may be 
reversible, so it should be monitored carefully for ototoxicity [24].
• Nephrotoxicity: it is because the accumulation and retention of aminoglycoside 
in the proximal tubular cells and the initial manifestations of damage at this 
site are mild proteinuria and hyaline and granular casts, and also the glomeru-
lar filtration rate is reduced after several additional days [24].
2.2.7 Principal drug interactions
See Table 4.
2.2.8 Important
• Streptomycin is not available always in some regions and it is administered only 
intramuscularly or intravenously, so it is a disadvantage [2].
• Gentamicin has replaced streptomycin for some indications because the toxicity of 
gentamicin is renal and mostly reversible although streptomycin is most vestibular 
compromise and irreversible [24].
2.3 Gentamicin
2.3.1 Mechanism of action
Gentamicin is a bactericidal aminoglycoside. It binds to the 30S ribosomal 
subunit and interferes with initiation of protein synthesis causing misreading of 
mRNA, premature termination of translation, and incomplete synthesized protein, 
creating nonfunctional proteins [24, 33].
2.3.2 Antimicrobial activity
Gram-negative bacteria such as Pseudomonas aeruginosa, Proteus species, Escherichia 
coli, Klebsiella species, Enterobacter species, Serratia, Citrobacter, and Staphylococcus 
species [24].
Drug Risk rating Interaction Mechanism Management
Colistimethate Consider 
therapy 
modification
Aminoglycosides 
may enhance the 
nephrotoxic and 
neuromuscular-
blocking effect of 
colistimethate
Additive nephrotoxic 
effects
Alteration in membrane 
permeability that leads 
to cellular lysis by 
colistimethate [29, 30]
This combination 
should be avoided, 
if they must be used 
together to monitor 
patients’ renal and 
neuromuscular 
function
Penicillins Consider 
therapy 
modification
Penicillins 
may decrease 
the serum 
concentration of 
aminoglycosides
Inactivation of 
aminoglycosides by 
extended spectrum 
penicillins, especially 
in renal dysfunction 
[31, 32]
Monitor serum 
aminoglycoside 
concentration, and do 
not administer dose 
together through the 
same IV line
Table 4. 
Principal drug interactions of streptomycin.
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2.3.3 Pharmacokinetics
See Table 5.
2.3.4 Administration
• IM: it should be administered by deep IM route.
• IV: infuse over 30–120 minutes [27].
2.3.5 Risk assessment
During therapy with gentamicin, you should monitor parameters like: urinaly-
sis, urine output, BUN, serum creatinine, plasma gentamicin levels (before and 
after the third dose), hearing tests before, during and after treatment especially in 
prolonged therapy [36, 37].
• Therapeutic peak: 5 and 12 μg/mL [36, 37].
2.3.6 Adverse effects
• Nephrotoxicity: usual risk factors include preexisting renal impairment, 
concomitant nephrotoxicity drugs, advanced age, and dehydration. If nephro-
toxicity occurs, it is better to discontinue therapy because the renal damage is 
usually reversible [24, 38].
• Ototoxicity: use with caution in patients with preexisting vertigo, tinnitus or 
hearing loss [24, 38].
• Neuromuscular blockade: aminoglycosides may inhibit prejunctional release of 
acetylcholine reducing postsynaptic sensitivity to the transmitter, and this reaction 
can follow intravenous, intramuscular or even oral administration of this antibiot-
ics, especially with concomitant use of anesthesia and other neuromuscular block-
ing agents. It can be reversed by intravenous administration of calcium salt [24].
2.3.7 Principal drug interactions
See Table 6.
Absorption Intramuscular: rapid and complete
Oral: poorly absorbed
Time to peak: IM 30–90 minutes; IV: 30 minutes after 30-minute infusion
Distribution Primarily into extracellular fluid, renal cortex. Poor penetration in cerebrospinal fluid 
(CSF) and ocular tissues
Vd: children: 0.35 L/kg; adults: 0.2–0.3 L/kg
Protein binding: <30%
Metabolism Minimal metabolism
Excretion Half-life elimination: adults 2 hours, renal failure: 41–24 hours
Urine: >70% as unchanged drug
Clearance is decreased in renal impairment
Table 5. 
Pharmacokinetic parameters of gentamicin [24, 34, 35].
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2.4 Rifampin
2.4.1 Mechanism of action
Rifampin is a bactericidal drug that kills cell growing and it binds to the beta 
subunit of DNA-dependent RNA polymerase (rpoB) to form a drug-enzyme 
complex blocking the chain formation in RNA transcription [44].
2.4.2 Antimicrobial activity
It inhibits most Gram-positive bacteria and Gram-negative microorganisms 
such as Escherichia coli, Pseudomonas, Proteus, and Klebsiella, and also it is  
active again Neisseria meningitidis, Haemophilus influenzae, and Mycobacterium 
tuberculosis [44].
2.4.3 Pharmacokinetics
See Table 7.
Drug Risk 
rating
Interaction Mechanism Management
Amphotericin B Monitor 
therapy
Amphotericin B 
may enhance the 
nephrotoxic effect 
of aminoglycosides
Unknown.
Probably synergism [39]
Monitor renal 
function
Bisphosphonate 
derivatives
Monitor 
therapy
Aminoglycosides 
may enhance the 
hypocalcemic effect 
of bisphosphonate 
derivates [40]
Association of 
aminoglycosides with 
hypocalcemia, probably 
inhibition of the activity 
of the parathyroid glands 
reducing parathyroid 
hormone production [40, 41]
Monitor serum 
calcium, serum 
magnesium and 
serum creatinine 
and renal function 
during concomitant 
use
Furosemide, 
bumetanide, 
torsemide (loop 
diuretics)
Monitor 
therapy
Diuretics 
may enhance 
nephrotoxicity 
and ototoxicity of 
aminoglycosides
Uncertain.
Damage in proximal 
tubular cells and decrease 
glomerular filtration rate. 
[42, 43]
Monitor toxic effects 
or avoid concomitant 
use except in 
life-threatening 
situations
Table 6. 
Principal drug interactions of gentamicin.
Absorption Oral: well absorbed (bioavailability 68%). Food may delay or reduce peak by one-third. It 
should be taken on an empty stomach
Time to peak serum: oral: 2–4 hours
Distribution Good penetration into many tissues and crosses CSF
Vd: 53 L/kg
Protein binding: 80%
Metabolism Microsomal B-esterases and cholinesterases. Also, 85% liver metabolism (potently 
induction CYP 1A2, 2C9, 2C19 and 3A4) and enterohepatic recirculation
Excretion Half-life elimination: 3–4 hours, prolonged with hepatic impairment feces (60%) and urine 
(30%) as unchanged drug
Table 7. 
Pharmacokinetic parameters of rifampin [34, 44–46].
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2.4.4 Administration
• IV: administer IV preparation by slow infusion rate IV over 30 minutes to 3 hours, 
monitor administration to prevent extravasation.
• Do not administer IM or SC.
• Oral: administer on an empty stomach with a glass of water to increase 
absorption [44].
2.4.5 Risk assessment
During the therapy with rifampin, it should be monitored with periodical liver 
function test, CBC, and therapeutic drug monitoring of rifampin [47].
2.4.6 Adverse effects
• Hypersensitivity reactions: cases of severe cutaneous adverse reactions like 
Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with 
eosinophilia. It is mediated by hypersensitivity type I (IgE). It requires discon-
tinue of therapy and management of the symptoms [48].
• Flu-like syndrome: symptoms of fever, chills, headache related with the use of 
oral rifampin. It is related with regimens of >600 mg once or twice 
 weekly, and it resolves spontaneously. Flu-like syndrome is mediated by 
hypersensitivity type III (antibodies against rifampicin IgM that produce 
immunocomplex) [48, 49].
• Hematologic effects: it may cause thrombocytopenia, leukopenia, or anemia. 
The platelets are damaged by complement activation following the formation 
of drug-antibody complex [48, 50].
• Hepatotoxicity: it may cause hepatic dysfunction especially if it is used with 
other hepatotoxic agents [44].
2.4.7 Principal drug interactions
Most of the interactions of rifampin are because it is a strong inducer of CYP3A4 
and CYP2C19, moderate inducer of CYP2C8 and CYP2C9, and P-glycoprotein 
inducer (Table 8) [51].
2.4.8 Important
• In children, pregnant or lactating women rifampin should not be used 
except where tetracyclines are contraindicated or when there are limitations 
on the use of streptomycin or gentamicin and it should not be used  
alone [1, 6, 9].
• It can be an alternative treatment for doxycycline or aminoglycosides, but 
the use of rifampin should be restricted in endemic areas of tuberculosis 
because monotherapy with rifampin can lead to the selection of resistant 
Mycobacterium tuberculosis strains [1, 3, 6, 9].
11
Update of Antibiotic Therapy of Brucellosis
DOI: http://dx.doi.org/10.5772/intechopen.86325
2.5 Ciprofloxacin
2.5.1 Mechanism of action
The fluoroquinolones inhibit two bacterial enzymes: DNA gyrase (in many 
Gram-negative bacteria) and topoisomerase IV (in many Gram-positive bacteria) 
blocking the DNA bacterial replication. This action results in damage of bacterial 
DNA and cell death being bactericidal agents [56, 57].
2.5.2 Antimicrobial activity
It is a bactericidal agent against Proteus, E. coli, Klebsiella, Salmonella, Shigella, 
Enterobacter, and Campylobacter [56].
2.5.3 Pharmacokinetics
See Table 9.
Drug Risk rating Interaction Mechanism Management
Apixaban Avoid 
combination
Rifampin is a strong 
inducer CYP3A4 and 
may decrease the 
serum concentration 
of apixaban
Induction of 
the CYP3A4-
mediated 
metabolism of 
apixaban [52]
Avoid concurrent 
use
Esomeprazole Avoid 
combination
Rifampin may 
decrease the serum 
concentration of 
esomeprazole
Rifampin 
induction of 
CYP3A4- and 
CYP2C19-
mediated 
esomeprazole 
metabolism [53]
Avoid concomitant 
use
Risperidone Consider 
therapy 
modification
Rifampin is a CYP3A4 
inducer that may 
decrease the serum 
concentration of 
risperidone [46]
Unknown.
Enzyme-
inducing drugs 
may decrease 
risperidone [54]
Consider increasing 
the dose of oral 
risperidone (no 
more than double 
the original dose) if 
a CYP3A4 inducer is 
initiated
Table 8. 
Principal drug interactions of rifampin [55].
Absorption Oral: well absorbed
Bioavailability: 70%. Avoid taking with most antacids and milk
Distribution Widely distributed in kidneys, gallbladder, liver, lungs, gynecological tissue, and prostatic 
tissue
Protein binding: 20–40%
Vd: 2.1–2.7 L/kg
Metabolism Poor hepatic metabolism and forms 4 metabolites, inhibitor of CYP1A2
Excretion Half-life elimination: children: 4–5 hours and adults: 3–5 hours, prolonged in older adults 
and in renal impairment
Urine 50% as unchanged drug), feces (15%)
Table 9. 
Pharmacokinetic parameters of ciprofloxacin [55, 56].
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2.5.4 Administration
• Oral: administer with food to minimize GI symptoms, avoid antacid use, milk, 
yogurt or calcium-fortified juices alone.
• IV: administer by slow IV infusion over 60 minutes [56].
2.5.5 Risk assessment
During the treatment with ciprofloxacin parameters like: CBC, renal and hepatic 
function, signs and symptoms of tendonitis should be monitored [56].
2.5.6 Adverse effects
• Gastrointestinal: nausea, vomiting, and abdominal discomfort [56].
• Neurologic: headache and dizziness, peripheral neuropathy, it can occur at 
any time during treatment and can last for months to years after finishing the 
treatment [58].
• Musculoskeletal: tendon rupture or tendinitis usually of the Achilles tendon, 
arthralgias, and join pain are reported, especially in ancient people and 
patients taking corticosteroids [59, 60].
• QT interval prolongation and arrhythmia: it may be produced by inhibition of 
potassium channels encoded by the KCNH2 gene (HERG gene). Ciprofloxacin 
use should be avoided in patients with a history of QT prolongation, torsade de 
pointes, uncorrected hypokalemia, cardiac disease or concomitant use of other 
medications that prolong the QT interval [56, 61].
2.5.7 Principal drug interactions
See Table 10.
Drug Risk rating Interaction Mechanism Management
Antacids, 
multivitamins 
and minerals 
like folate and 
iron
Consider 
therapy 
modification
Antacids may 
decrease the 
absorption of 
quinolones
The carbonyl 
functional groups on 
the antibiotic forms 
a chelate with the 
cations of the antacid 
resulting in inactive 
antimicrobials  
[62, 63]
Avoid concurrent 
administration of 
quinolones and 
antacids or quinolones 
should be administered 
at least 2 hours before 
or 2 hours after antacids 
or 6 hours after 
multivitamins
Theophylline Consider 
therapy 
modification
Quinolones may 
decrease the 
metabolism of 
theophylline
Quinolone inhibition 
of CYP1A2 and 
CYP3A4 isoenzymes 
limiting the 
metabolism of 
theophylline [64, 65]
Consider a reduction 
in the dosage of 
theophylline (25–50%) 
during the concurrent 
use to minimize the 
theophylline toxicity
Table 10. 
Principal drug interactions of ciprofloxacin.
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2.5.8 Important
• It may be useful in the setting of drug resistance, antimicrobial toxicity, and 
some cases of relapse.
2.6 Trimethoprim-sulfamethoxazole (TMP/SMX)
2.6.1 Mechanism of action
The combination of trimethoprim with sulfamethoxazole enhances the 
effectivity and synergist antimicrobial activity. TMP inhibits bacterial dihydro-
folate reductase preventing the formation of tetrahydrofolic acid, and SMX is 
a structural analog of the para-aminobenzoic acid (PABA), and it binds to the 
dihydropteroate synthetase and competes with PABA to inhibit the synthesis of 
dihydrofolic acid [56, 66].
2.6.2 Antimicrobial activity
The antibacterial spectrum is most S. pneumoniae, S. aureus, and Staphylococcus 
epidermidis, some E. coli according to the geographic region, Proteus mirabilis, 
Klebsiella, Enterobacter, also Brucella abortus [56].
2.6.3 Pharmacokinetics
See Table 11.
2.6.4 Administration
• Oral: administer without regard to meals and a lot of water.
• IV: infuse over 60–90 minutes, and it is not administered by IM injection [56].
2.6.5 Risk assessment
Some monitoring parameters during the treatment are CBC, serum potassium, 
creatinine, and BUN [56].
Absorption Oral: rapid 90–100%, TMP is absorbed more rapidly than sulfamethoxazole, 
bioavailability of 85%
Distribution Good penetration in middle ear fluid, sputum, vaginal fluid, and bronchial 
secretions
Vd: adults: 1.3 L/kg
Protein binding: SMX 70%, TMP 44%
Metabolism Hepatic, SMX via CYP2C9 and also conjugated with glucuronide; TMP to oxide 
and hydroxy derivatives
Excretion Half time elimination: TMP: children 3.7–5.5 hours and adults: 6–11 hours. SMX 
9–12 hours
Both excreted in urine as metabolites and unchanged drug
Table 11. 
Pharmacokinetic parameters of TMP/SMX [56].
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2.6.6 Adverse effects
• Blood dyscrasias: agranulocytosis, aplastic anemia, leukopenia, or thrombo-
cytopenia because of the margin between toxicity for bacteria and humans 
related with folate deficient [67].
• Neurologic effects: it is associated with adverse neurologic events like aseptic men-
ingitis, tremor, delirium because TMP/SMX crosses the blood-brain barrier [67].
• Dermatologic reactions: severe reactions including Stevens-Johnson syndrome 
produced by immune-mediated idiosyncratic reactions associated with reac-
tive metabolite leading to drug-specific antibodies [67].
• Hyperkalemia: it is produced because of the TMP similar structure to potassium-
sparing diuretics. Potential risk factors include renal impairment, older age, and 
concomitant use of medications causing or exacerbating hyperkalemia [56].
2.6.7 Principal drug interactions
See Table 12.
2.6.8 Important
• TMP-SMX may be used as an additional agent in complex cases of focal brucel-
losis, relapse, or refractory disease [2].
• TMP-SMZ should not be used in pregnancy, either before 13 weeks because of the 
risk of teratogenic effects or after 36 weeks because of the risk of kernicterus [21].
• It has been a popular choice and it is included in combination regimens around 
the world, due to its lower cost compared to other antimicrobials being the 
most cost-effective drug against brucellosis in developing countries [2].
• No alternative anti-brucellosis therapy for children under 8 years old has been 
reported, but there is a case that had a 2.5 years old patient with brucellosis 
Drug Risk rating Interaction Mechanism Management
Phenytoin Consider 
therapy 
modification
TMP/SMX may 
increase the serum 
concentration of 
phenytoin
TMP inhibition of 
CYP2C8 and CYP2C9-
mediated phenytoin 
metabolism [68]
Consider alternatives 
to this combination 
when possible
Warfarin Consider 
therapy 
modification
TMP/SMX may 
enhance the 
anticoagulant 
effect of vitamin K 
antagonists
Multifactorial.
Sulfonamide 
displacement of 
warfarin from 
protein binding sites, 
reductions in GI 
flora responsible for 
production of vitamin 
K [69, 70]
Monitor toxic 
effects of warfarin. 
Consider reducing 
warfarin dose 
by 10–20% 
prior starting 
the sulfonamide 
antibiotic and 
monitoring INR 
closely [71]
Table 12. 
Principal drug interactions of TMP/SMX.
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with TMP-SMX allergy, they use as an alternative for treatment ciprofloxacin 
having a good result of the treatment and continue follow up visits, but there 
are no evidence enough for this treatment, so it is necessary to search for 
alternative treatment for this patient population [12].
3. Other considerations about treatment
• Doxycycline is the drug of choice in the treatment of brucellosis, but antibi-
otic susceptibility patterns of Brucella appears to vary geographically, that is 
why tigecycline can be an option for treatment in brucellosis. Tigecycline is a 
glycylcycline derivate from tetracycline and minocycline. It has demonstrated 
activity against Enterobacteriaceae, Gram-positives, atypical, and anaerobes. It 
has the lowest minimal inhibitory concentration on in vitro efficacy models, 
and also it provided the better synergistic activity compared to doxycy-
cline. Tigecycline can be a therapeutic alternative for brucellosis especially 
in patients in whom conventional antibiotics is contraindicated or limited 
because of the presence of severe comorbidities or drug-drug interactions, but 
it should be supported with more clinical studies [72].
• There are some regional experience and some different treatments that differs 
according the regional experiences but here are some considerations:
 ○ The World Health Organization (WHO) recommends the use of doxycycline 
for 6 weeks combined with rifampicin for 6 weeks, or streptomycin for 
2–3 weeks, but this regimen has not been universally used in clinical prac-
tice. Even this fact it remains unclear what is the best regimen to be used and 
more clinical studies are needed in this regard [2].
 ○ From the comparison of regimens that can be established in random-
ized clinical trials are: doxycycline and streptomycin vs. doxycycline and 
rifampicin that favors the first combination in terms of relapse (OR 3.52; CI 
95% = 2.14–5.81; p < 0.001); doxycycline and streptomycin vs. doxycycline 
and gentamicin is not statistically significant as regards either relapses 
(OR = 1.65; CI 95% = 0.53–5.15; p = 0.386); doxycycline and rifampicin vs. 
doxycycline and quinolone favors the first one (OR 3.92; CI 95% = 1.35–
11.42; p = 0.01) [73].
 ○ The most effective regimen is combined doxycycline for 45 days with strep-
tomycin for 14 days, in endemic areas where many patients have a mild form 
of the disease and diagnosis and prescription can be made in the urgency 
room the used to use gentamycin for the first 5–7 days [4, 73].
 ○ About the comparison of the efficacy of gentamicin for 5 days plus 
 doxycycline for 8 weeks vs. streptomycin for 2 weeks plus doxycycline 
for 45 days in human brucellosis, there is a clinical trial that compare the 
efficacy  showing that this treatment is not superior to the standard treat-
ment  regimen [74].
 ○ There are a few studies using doxycycline, rifampicin, and aminoglycosides vs. 
other regimens in uncomplicated brucellosis with no conclusions on the value 
of this triple therapy, also some studies were performed only in patients with 
osteoarticular complications. Another option for triple therapy is doxycycline, 
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rifampin, and amikacin (intramuscularly twice a day for 7 days) that have 
higher efficacy and more rapid action in terms of relief of symptoms, but it has 
no significant difference in drug side-effects and disease relapse, thus adding 
amikacin to the standard treatment regimen seems beneficial [6, 75].
4. Conclusion
In conclusion, there are some antibiotic therapies that are approved for the treat-
ment of brucellosis, and some of them are in prolonged therapy that could affect 
the adherence of the patient and some of the antibiotics have important recommen-
dations and need to be used in some conditions. Also, they have some parameters 
that may be monitorable to prevent adverse effects and to improve the outcome of 
the treatment in all the patients.
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Appendices and nomenclature
CBC complete blood count
GI gastrointestinal
h hours
IM intramuscular
IV intravenous
kg kilograms
mg milligrams
MIC minimum Inhibitory concentration
TMP/SMX trimethoprim-sulfamethoxazole
Vd volume of distribution
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